Clinical Trials
10 trialsNCT05882734 2026-05-28
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
EMD Serono
Phase 1/2 Active not recruiting
NCT06162572 2026-05-11
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Servier
Phase 1/2 Active not recruiting
NCT06923761 2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2 Recruiting
NCT05259696 2025-08-20
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting
NCT06088771 2025-05-08
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT06090266 2025-01-07
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Recruiting
NCT05501665 2024-10-17
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Recruiting
NCT05094804 2023-11-02
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Unknown
NCT03367819 2022-05-16
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Sanofi
Phase 1/2 Terminated